DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy

European Journal of Nuclear Medicine

Volumn 24, Issue 7, 1997, Pages 792-795

  Otte, A ^a   Jermann, E ^a   Behe, M ^a   Goetze, M ^a   Bucher, H C ^a   Roser, H W ^a   Heppeler, A ^a   Mueller Brand, J ^a   Maecke, H R ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

DOTA D Phe1 Tyr3 octreotide (DOTATOC); DTPA D Phe1 octreotide (OctreoScan); Indium 111; Somatostatin receptor mediated internal radiotherapy; Yttrium 90

Indexed keywords

INDIUM 111; PENTETREOTIDE; PEPTIDE; RADIOISOTOPE; SOMATOSTATIN RECEPTOR; YTTRIUM 90;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NEUROENDOCRINE TUMOR;

ABDOMINAL NEOPLASMS; ADULT; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PENTETIC ACID; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; YTTRIUM RADIOISOTOPES;

EID: 0030737659     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050122     Document Type: Article

References (3)

1. Krenning EP, Bakker WH, Breeman WAP, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; I: 242-244.
2. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumours. N Engl J Med 1990; 323: 1246-1249.
3. Sivolapenko GB, Douli V, Pectasides D, et al. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody. Lancet 1995; 346: 1662-1666.